BeyondSpring Inc. BYSI

BYSI Company Overview

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies and supportive care treatments. The company operates within the biotechnology and oncology industries, with research efforts centered on therapies designed to improve outcomes for patients with high unmet medical needs. BeyondSpring is best known for developing plinabulin, a selective immunomodulating microtubule-binding agent that has been evaluated for chemotherapy-induced neutropenia (CIN) prevention and multiple oncology indications. The company has historically generated limited commercial revenue and has primarily relied on financing activities, licensing arrangements, and research collaborations to support operations.

BeyondSpring was founded in 2010 and is headquartered in New York, United States, with operational and research activities extending into China and other international markets. The company became publicly listed on the Nasdaq under the ticker BYSI and has evolved from an early-stage oncology research enterprise into a broader immuno-oncology development company. Its strategic positioning has centered on leveraging proprietary drug development platforms and pursuing differentiated oncology therapies intended to complement or enhance existing standards of care.